CBP9106
Oncology (unspecified)
Preclinical/Phase 1Active
Key Facts
About CanBas
Japanese oncology biotech developing small molecule DNA damage response inhibitors to enhance cancer treatment efficacy.
View full company profileTherapeutic Areas
Other Oncology (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Vaccine Program | CHAIN Biotech | Pre-clinical |
| ARX305 | NovoCodex Biopharmaceuticals | Phase 1 |
| ARX788 | NovoCodex Biopharmaceuticals | Phase 1 |
| Cancer Immunotherapy Nanotherapeutic | Flashpoint Therapeutics | Phase 1 |
| GRWD5769 | Greywolf Therapeutics | Phase 1/2 |
| Platform-derived Program(s) | Immuto Scientific | Discovery/Pre-clinical |
| MBT Oncology Program | Ionic Pharmaceuticals | Pre-clinical |
| ISB 2301 | Ichnos Glenmark Innovation | Preclinical |
| GRC 65327 | Ichnos Glenmark Innovation | Preclinical |
| Platform-Derived Pipeline | Phinomics | Discovery/Pre-clinical |
| Lead Small-Molecule Inhibitor | Eris Biotech | Pre-clinical |
| Orotecan™ | Edison Oncology | Phase 1/2a |